Parkinson's Archives - Purablis-Medicinal Tinctures with CBD, THCA and THC

Parkinson’s Marijuana Studies and

Parkinson’s Cannabis Research


Author(s): Marcos Hortes N Chagas, Antonio W Zuardi, Vitor Tumas, Márcio Alexandre Pena-Pereira, Emmanuelle T Sobreira, Mateus M Bergamaschi, Antonio Carlos dos Santos, Antonio Lucio Teixeira, Jaime EC Hallak and José Alexandre S Crippa.

CBD has a promising use to improve the quality of life of patients with Parkinson’s disease without psychiatric comorbidities. View study


Author(s): Sandeep Vasant More and Dong-Kug Choi*.

The use of cannabinoids as a new therapeutic target has been recommended as a promising therapy for Parkinson’s disease, as the growing evidence suggests a prominent modulating function of the cannabinoid signaling system in the basal ganglia. View study


Author(s): Katerˇina Venderova´, PharmD, PhD, Evzˇen Ru˚zˇicˇka, MD, DSc, Viktor Vorˇı´sˇek, PharmD, and Peter Visˇnˇovsky´, MD, PhD.

Interesting questionnaires that show that bradykinesia seems to be the symptom most commonly improved by cannabinoids, followed by muscle rigidity and tremor. In addition, the use of cannabis causes the relief of dyskinesias induced by dopaminergics. View study


Author(s): Marta Celorrio a, b, Estefanía Rojo-Bustamante a, b, Diana Fernandez-Su  arez  a, Elena Saez  c, Ander Estella-Hermoso de Mendoza c, Christa E. Müller d, María J. Ramírez e, g, Julen Oyarzabal  c, Rafael Franco a, f, María S. Aymerich.

For the first time it is demonstrated that the activation of the GPR55 receptor by. View study


Author(s): M. H. N. Chagas MD PhD, A. L. Eckeli MD PhD, A. W. Zuardi MD PhD, M. A. Pena-Pereira MD, M. A. Sobreira-Neto MD, E. T. Sobreira PhD, M. R. Camilo MD, M. M. Bergamaschi PhD, C. H. Schenck MD, J. E. C. Hallak MD PhD, V. Tumas MD PhD and J. A. S. Crippa MD PhD.

A synthetic cannabidiol isomer (CBD) may be beneficial in combating Parkinson’s disease. View study


Author(s): Lu Song Xinxin Yang Yaping Ma Na Wu Zhenguo Liu.

The dopamine precursor L-3,4-dihydroxyphenylalanine (L-DOPA) has been used effectively to treat Parkinson’s disease. However, its long-term administration produces serious complications. In this study, the active participation of CB1 receptors in the regulation of the action of L-DOPA during the treatment of Parkinson’s Disease is evidenced. View study


Author(s): S G Fagan and V A Campbell.

Modulation of the cannabinoid system has shown beneficial effects and constitutes a possibility for the treatment of neurodegenerative disorders such as Parkinson’s disease. View study